A Phase 3 interventional study of Custodiol-N and Custodiol in Aortic Valve Disease and Coronary Artery Disease (CAD), sponsored by Dr. F. Köhler Chemie GmbH. Completed at 6 sites in Germany. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-18.
Sponsored by Dr. F. Köhler Chemie GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Aortic Valve Disease with a site in Germany — 10 open to participants now, 13 under way, none of them phase 3. Aortic Valve Disease · Germany.
Among the 44 studies in Aortic Valve Disease with a site in Germany, this one is the 7th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 3, and was the 15th registered.
234 studies on the registry are indexed under Aortic Valve Disease; 70 are open to participants now.
Browse Aortic Valve Disease studies →10 of the 44 studies in Aortic Valve Disease with a site in Germany are open now. Recruiting first, the newest first:
Edwards Lifesciences · Sites in Germany
Ages 18+
Heart Center Leipzig - University Hospital · Sites in Germany
Ages 18–75
Edwards Lifesciences · Sites in Germany
Ages 18+
Heinrich-Heine University, Duesseldorf · Sites in Germany
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2014.
This study's enrollment of 530 is above the median of 111 across 125 interventional studies indexed under Aortic Valve Disease.
Median enrollment 155 across the 23 interventional studies, 260 across the 21 observational. Of the 26 that completed or were terminated, 8 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 44 have an industry lead sponsor. The 10 most frequent:
Dr. F. Köhler Chemie GmbH is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Dr. F. Köhler Chemie GmbH has 1 study filed under Aortic Valve Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Aortic Valve Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07120048Edwards LifesciencesReal World Data Collection on the INSPIRIS RESILIA Aortic Valve | 2026-12 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Aortic Valve Disease with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this investigation is to compare the cardioprotective effects and safety of two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients undergoing aortic valve surgery. The study design is a prospective, double blind, multicenter, randomized, Phase III comparison study intended to demonstrate superiority in surgical outcome between Custodiol and Custodiol-N as determined by CK-MB peak value 4-24 hours after opening of the aortic cross-clamp (primary endpoint), catecholamine requirement (cumulative dose) and cardiac Troponin T, occurrence of comorbid events postoperatively (e.g., myocardial infarction).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Drug: Custodiol-N
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Drug: Custodiol
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Drug pages: Histidine · Tryptophan · Ketoglutaric Acids · Mannitol · Sodium Chloride · Potassium Chloride · Magnesium Chloride · Calcium Chloride
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
peak value for CK-MB
Time frame: measured at 4, 8, 12, 16, 20 and 24 hours after the release of the aortic cross clamp
Catecholamine requirement on SICU
Time frame: within 24 hours (cumulative dose)
Safety parameters
documentation and reporting of AE and SAE
Time frame: from time of the study inclusion up to the follow-up visit on day 5
Ran from May 2014 to primary completion in Nov 2018, 54 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Custodiol-N solution · Histidine · Tryptophan · Ketoglutaric Acids · Mannitol · Sodium Chloride · Potassium Chloride · Magnesium Chloride · Calcium Chloride
Dr. F. Köhler Chemie GmbH